Coherus BioSciences Announces Filing of Patent Infringement Suit Against Amgen Directed to Amgen’s Humira Biosimilar Formulation

Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced it has filed suit against Amgen in the United States District Court (Delaware) alleging that Amgen's Humira® biosimilar, Amgevita™, infringes Coherus' U.S. patents 10,155,039; 10,159,732; and 10,159,733. Each of the asserted Coherus patents is directed to stable formulations of adalimumab.

"Coherus recognized early on the central role intellectual property would play in advancing biosimilars to market," said Denny Lanfear, Chairman, CEO and President of Coherus. He continued, "One important element of our IP strategy for advancing our Humira® biosimilar (CHS-1420) is reflected in the success we've achieved in patenting our innovations in the field of adalimumab formulation. We believe in the strength of our IP and we intend to protect it."

Coherus' Humira® biosimilar candidate, CHS-1420, is among a number of significant biosimilar candidates in Coherus' pipeline of high-value treatments for patients in need, including biosimilar candidates directed to Enbrel®, Lucentis®, and Eylea®.

Coherus is currently preparing its biologics license application for CHS-1420 for submission to the U.S. Food and Drug Administration, with anticipated filing in late 2019. Upon the expected U.S. market launch of CHS-1420 in late 2023, the company believes it will be well-positioned to effectively leverage the commercial infrastructure it has already deployed for its recent U.S. launch of UDENYCA™ (pegfilgrastim-cbqv). The company continues to evaluate options and potential strategies for ex-U.S. commercialization of CHS-1420. 

Register as Visitor to CPhI China 2019!